Cell & Gene: The Podcast

By: Erin Harris
  • Summary

  • Cell & Gene, the most valuable online resource for delivering in-depth content from authoritative authors and sources to professionals in the CGT sector, introduces Cell & Gene: The Podcast. In each episode, Cell & Gene Chief Editor, Erin Harris, will talk to industry and academic leaders about their current initiatives and how they are moving the sector forward.
    © 2024 Cell & Gene: The Podcast
    Show more Show less
activate_Holiday_promo_in_buybox_DT_T2
Episodes
  • Improving TCR T-Cell Persistence and Efficacy with Adaptimmune's Dennis Williams
    Nov 7 2024

    We love to hear from our listeners. Send us a message.

    On this episode of Cell & Gene: The Podcast, Host Erin Harris talks to Dennis Williams, Senior Vice President of Late Stage Development at Adaptimmune. Williams shares valuable insights into the groundbreaking world of TCR T-cell therapies, with a particular focus on the TECELRA trial. The trial led to the FDA approval of Tecelra, marking a significant milestone as the first engineered T-cell therapy for solid tumors. Williams delves into the complexities of developing this innovative treatment for synovial sarcoma, a rare and aggressive form of soft-tissue cancer. He also highlights the unique challenges and promising outcomes associated with TCR T-cell therapies, offering a comprehensive understanding of this cutting-edge approach in cancer immunotherapy.

    Subscribe to the podcast!
    Apple | Spotify | YouTube

    Show more Show less
    21 mins
  • Live from ARM's Meeting on the Mesa with Kiji Therapeutics' Dr. Miguel Forte
    Oct 24 2024

    We love to hear from our listeners. Send us a message.

    This episode of Cell & Gene: The Podcast was recorded on site during ARM's 2024 Meeting on the Mesa in Phoenix. Tune in to hear Host Erin Harris talk to Miguel Forte, M.D., Ph.D., CEO of Kiji Therapeutics, President of ISCT, and Executive Committee Member of ARM about Kiji's clinical plan and why iPSC-MSC therapy for inflammatory diseases shows great promise. They also cover this year's conference and what to expect during and after the event.

    Subscribe to the podcast!
    Apple | Spotify | YouTube

    Show more Show less
    25 mins
  • Pioneering Next-Gen TCR Therapies in Solid Tumors with Neogene Therapeutics’ Carsten Linnemann, Ph.D.
    Oct 10 2024

    We love to hear from our listeners. Send us a message.

    Carsten Linnemann, Ph.D., CEO of Neogene Therapeutics and Head of Oncology Cell Therapy Clinical Development, AstraZeneca joins Cell & Gene: The Podcast’s Erin Harris to discuss T-cell receptor (TCR) therapies for solid cancers. They talk through key challenges and opportunities in developing TCR therapies targeting neoantigens as well as the potential benefits of TCR-T therapies for cancer treatment. Linnemann shares his thoughts on the future landscape of cell therapy in oncology and beyond. Previous episodes of Cell & Gene: The Podcast have focused on TCR therapies, including Episode 50, featuring Affini-T Therapeutics’ Co-Founder, CEO, and President Dr. Jak Knowles. Be sure to check out that episode, too.

    https://www.cellandgene.com/doc/targeting-oncogenic-drivers-for-solid-tumor-cancers-with-affini-t-therapeutics-dr-jak-knowles-0001

    Subscribe to the podcast!
    Apple | Spotify | YouTube

    Show more Show less
    14 mins

What listeners say about Cell & Gene: The Podcast

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.